Entity type
Individual
Filer Snapshot
Michael L. Meyers
CIK 0001664204. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.
Total filings
3
Latest filing
16 Jun 2023
Industry
n/a
Filing-backed research brief
Start with the SEC data that changes for this CIK
Latest signal: Forms 3/4/5 owner position for SNDX. Each card links back to the PortfolioSavvy page where the filing evidence is closest.
Latest 13F portfolio
—
No parsed 13F portfolio row yet.
Browse latest 13FLargest parsed holding
—
Populates from the latest parsed 13F information table.
Open holding13D/G large stake
—
No recent parsed 13D/G stake row for this CIK.
Browse 13D/GInsider / owner context
SNDX
02 Feb 2022 · $873.6K
Open owner pageSave this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Source: SEC Forms 3/4/5
View Source Filing
4 filed on 16 Jun 2023 for CIK 0001664204.
- SEC ownership summary
-
Value by filing family
These bars compare separate filing families; do not add them into one ownership total.
Forms 3/4/5 positions$1.26MReporting-owner positions when a value can be estimated.
Estimated reporting-owner value
$1.26M
Estimated from parsed Forms 3/4/5 when filings disclose enough data.
Largest SEC-reported positions
Largest issuer positions across supported ownership filing types.
SNDX NUVLHow to read filing-family values
- Keep filing families separate: 13F portfolio value, 13D/G large stakes, and Forms 3/4/5 reporting-owner positions are different evidence types.
- Use the linked research paths to verify each signal against the original SEC filing.
- Business address
- C/O Syndax Pharmaceuticals, Inc., 400 Totten Pond Road, Suite 110, Waltham, MA, 02451
SEC ownership signals
1 signal
Filer identity
1 identity field
Filer intelligence
What SEC filings say about Michael L. Meyers
A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.
Quick read
- Forms 3/4/5 show insider context for SNDX worth $873.6K.
SEC source mix
Counts show available parsed rows, not one combined ownership total.
Forms 3/4/5 insider context
SNDX
02 Feb 2022 · SVP, Chief Medical Officer
NUVL
18 Jun 2025
Latest update
What changed recently for Michael L. Meyers
Latest ownership report period: 18 Jun 2025. Open the source-backed page to inspect the fresh filing or facts context.
Update date
20 Jun 2025
Page type
Ownership filings
Latest period
18 Jun 2025
Ownership context was refreshed from SEC Forms 3/4/5 filed on 20 Jun 2025.
SEC filing record
CIK 0001664204 filing coverage
Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.
SEC filings
3
First seen
06 Oct 2022
Latest filing
16 Jun 2023
Entity
Individual
Observed form types
3
4
Latest Filings
Showing the latest 3 of 3 SEC filings for Michael L. Meyers.
4
4 filing
- Filing date
- 16 Jun 2023
- Reporting date
- 15 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 06 Oct 2022
- Reporting date
- 04 Oct 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
3
3 filing
- Filing date
- 06 Oct 2022
- Reporting date
- 04 Oct 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing